MX2024000213A - Métodos de uso y composiciones que incluyen un análogo de incretina. - Google Patents
Métodos de uso y composiciones que incluyen un análogo de incretina.Info
- Publication number
- MX2024000213A MX2024000213A MX2024000213A MX2024000213A MX2024000213A MX 2024000213 A MX2024000213 A MX 2024000213A MX 2024000213 A MX2024000213 A MX 2024000213A MX 2024000213 A MX2024000213 A MX 2024000213A MX 2024000213 A MX2024000213 A MX 2024000213A
- Authority
- MX
- Mexico
- Prior art keywords
- glycemic control
- weight management
- incretin analog
- glucagon
- incretin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163213956P | 2021-06-23 | 2021-06-23 | |
| PCT/US2022/034437 WO2022271767A1 (en) | 2021-06-23 | 2022-06-22 | An incretin analog for use in glycemic control and weight management |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024000213A true MX2024000213A (es) | 2024-04-16 |
Family
ID=82608370
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024000213A MX2024000213A (es) | 2021-06-23 | 2022-06-22 | Métodos de uso y composiciones que incluyen un análogo de incretina. |
| MX2025012713A MX2025012713A (es) | 2021-06-23 | 2024-01-03 | Metodos de uso y composiciones que incluyen un analogo de incretina |
| MX2025012714A MX2025012714A (es) | 2021-06-23 | 2024-01-03 | Metodos de uso y composiciones que incluyen un analogo de incretina |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025012713A MX2025012713A (es) | 2021-06-23 | 2024-01-03 | Metodos de uso y composiciones que incluyen un analogo de incretina |
| MX2025012714A MX2025012714A (es) | 2021-06-23 | 2024-01-03 | Metodos de uso y composiciones que incluyen un analogo de incretina |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US12496329B2 (enExample) |
| EP (1) | EP4358994A1 (enExample) |
| JP (1) | JP2024524180A (enExample) |
| KR (1) | KR20240024936A (enExample) |
| CN (1) | CN117915939A (enExample) |
| AU (2) | AU2022298662B2 (enExample) |
| BR (1) | BR112023027321A2 (enExample) |
| CA (1) | CA3223313A1 (enExample) |
| IL (1) | IL309604A (enExample) |
| MX (3) | MX2024000213A (enExample) |
| WO (1) | WO2022271767A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102812908B1 (ko) * | 2019-08-19 | 2025-05-28 | 일라이 릴리 앤드 캄파니 | 인크레틴 유사체의 제조 방법 |
| CN117320740A (zh) * | 2021-02-17 | 2023-12-29 | 伊莱利利公司 | Gip/glp1双重激动剂治疗方法 |
| WO2026037397A1 (zh) * | 2024-08-16 | 2026-02-19 | 江苏恒瑞医药股份有限公司 | Glp-1类似物的医药用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2548275T3 (es) | 2010-03-01 | 2015-10-15 | Eli Lilly And Company | Dispositivo de inyección automático con mecanismo de retardo que incluye un elemento de empuje de funcionamiento doble |
| KR102589234B1 (ko) | 2017-11-21 | 2023-10-16 | 일라이 릴리 앤드 캄파니 | 둘라글루티드를 함유하는 조성물 및 사용 방법 |
| AR113486A1 (es) | 2017-12-21 | 2020-05-06 | Lilly Co Eli | Análogos de incretina y sus usos |
| TWI767095B (zh) | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| CA3177693A1 (en) | 2019-04-05 | 2020-10-05 | Eli Lilly And Company | Therapeutic uses of dulaglutide |
| TW202140058A (zh) | 2020-01-30 | 2021-11-01 | 美商美國禮來大藥廠 | 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途 |
-
2022
- 2022-06-22 CA CA3223313A patent/CA3223313A1/en active Pending
- 2022-06-22 KR KR1020247002023A patent/KR20240024936A/ko not_active Ceased
- 2022-06-22 CN CN202280057356.1A patent/CN117915939A/zh active Pending
- 2022-06-22 US US18/573,779 patent/US12496329B2/en active Active
- 2022-06-22 JP JP2023578701A patent/JP2024524180A/ja active Pending
- 2022-06-22 EP EP22744035.1A patent/EP4358994A1/en active Pending
- 2022-06-22 IL IL309604A patent/IL309604A/en unknown
- 2022-06-22 AU AU2022298662A patent/AU2022298662B2/en active Active
- 2022-06-22 WO PCT/US2022/034437 patent/WO2022271767A1/en not_active Ceased
- 2022-06-22 MX MX2024000213A patent/MX2024000213A/es unknown
- 2022-06-22 BR BR112023027321A patent/BR112023027321A2/pt not_active Application Discontinuation
-
2024
- 2024-01-03 MX MX2025012713A patent/MX2025012713A/es unknown
- 2024-01-03 MX MX2025012714A patent/MX2025012714A/es unknown
-
2025
- 2025-08-22 AU AU2025220848A patent/AU2025220848A1/en active Pending
- 2025-11-18 US US19/393,199 patent/US20260091087A1/en active Pending
- 2025-11-18 US US19/393,216 patent/US20260091088A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024524180A (ja) | 2024-07-05 |
| US20260091088A1 (en) | 2026-04-02 |
| US20240325498A1 (en) | 2024-10-03 |
| EP4358994A1 (en) | 2024-05-01 |
| KR20240024936A (ko) | 2024-02-26 |
| AU2022298662A1 (en) | 2024-01-18 |
| CN117915939A (zh) | 2024-04-19 |
| IL309604A (en) | 2024-02-01 |
| AU2025220848A1 (en) | 2025-09-11 |
| US20260091087A1 (en) | 2026-04-02 |
| MX2025012714A (es) | 2025-11-03 |
| AU2022298662B2 (en) | 2025-06-05 |
| BR112023027321A2 (pt) | 2024-03-12 |
| US12496329B2 (en) | 2025-12-16 |
| MX2025012713A (es) | 2025-11-03 |
| WO2022271767A1 (en) | 2022-12-29 |
| CA3223313A1 (en) | 2022-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025012713A (es) | Metodos de uso y composiciones que incluyen un analogo de incretina | |
| Kvols et al. | Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. | |
| NZ771043A (en) | Gip and glp-1 co-agonist compounds | |
| ZA202106369B (en) | Gip/glp1 co-agonist compounds | |
| BR112023003668A2 (pt) | Agonistas duplos de glp-1/gip | |
| ZA202310867B (en) | Multi-agonist and use thereof | |
| JOP20220153A1 (ar) | نظائر الإنكرتين واستخداماتها | |
| DOP2025000003A (es) | Agonista dual de glp-1/gip, método de preparación y uso del mismo | |
| ZA202306729B (en) | Novel glp-1 analogues | |
| BR112022025615A2 (pt) | Agonistas duplos de glp-1/gip de ação prolongada | |
| EP4043026A4 (en) | GLUCAGON, GLP-1 RECEPTOR AND DGIP RECEPTOR DUAL AGONIST COMPOSITION AND THERAPEUTIC USE THEREOF | |
| CO2023012373A2 (es) | Composiciones que contienen análogos de incretina y usos de estas | |
| MX2026000195A (es) | Triagonista de los receptores glp-1, gip y gcg y su uso | |
| Tomkin | Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetes. | |
| EP4197550A4 (en) | PHARMACEUTICAL COMPOSITION WITH HYPOTENSIVE EFFECT COMPRISING A TRIPLE ACTIVATOR WITH ACTIVITY FOR ALL GLUCAGON, GLP-1, AND GIP RECEPTORS | |
| MX2024014840A (es) | Métodos de uso de un coagonista de gcg/glp1 para terapia | |
| Shehadeh et al. | Can GLP-1 preparations be used in children and adolescents with diabetes mellitus? | |
| Madsen et al. | A 45-fold liraglutide overdose did not cause hypoglycaemia | |
| Shimoda et al. | The Beneficial Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Dulaglutide on Plasma Glucose and Hemoglobin A1c Levels: A Case Report of Four Patients with Type 2 Diabetes | |
| Camafort-Babkowski | Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus | |
| Scheen et al. | Rationale supporting basal insulin-incretin combined therapies in type 2 diabetes | |
| Scheen | Albiglutide (Eperzan): a new once-weekly agonist of glucagon-like peptide-1 receptors |